Clinical use of new antithrombotic therapies for medical management of acute coronary syndromes

Pharmacotherapy

Volumn 21, Issue 3, 2001, Pages 320-337

  Wiggins, Barbara S ^a   Wittkowsky, Ann K ^a   Nappi, Jean M ^b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ARGATROBAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DESULFATOHIRUDIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; HIRULOG; INOGATRAN; LAMIFIBAN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; NAPSAGATRAN; NITRIC ACID DERIVATIVE; OXYGEN; STREPTOKINASE; THROMBIN INHIBITOR; TICLOPIDINE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR;

CLINICAL TRIAL; CORONARY STENT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; FIBRINOLYTIC THERAPY; HEART MUSCLE ISCHEMIA; HUMAN; PATHOPHYSIOLOGY; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ACUTE DISEASE; CORONARY DISEASE; FIBRINOLYTIC AGENTS; HUMANS;

EID: 0035099027     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.3.320.34211     Document Type: Review

References (86)

1. The pathogenesis of coronary artery disease and the acute coronary syndromes
2. Atherosclerosis - An inflammatory disease
3. Insights into the pathophysiology of unstable coronary artery disease
4. Advancing the battle against acute ischemic syndromes: A focus on the GP IIb-IIIa inhibitors
5. Glycoprotein IIb-IIIa receptor antagonists in the management of cardiovascular diseases
6. ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: Executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina)
7. Adjunctive intracoronary thrombolysis in complicated angioplasty
8. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: Results of a Veterans Administration cooperative study
9. Aspirin, sulfinpyrazone or both in unstable angina: Results of a Canadian multicenter trial
10. Aspirin, heparin, or both to treat acute unstable angina
11. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
12. A randomized, controlled trial with aspirin in persons recovered from myocardial infarction
13. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. For the heparin-aspirin reperfusion trial (HART) investigators
14. Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease
15. Combination antithrombotic therapy in unstable rest angina and non-Q wave infarction in nonprior aspirin users
16. Antithrombotic agents in coronary artery disease
17. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina
18. Reactivation of unstable angina after the discontinuation of heparin
19. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, considerations, monitoring, efficacy, and safety
20. Targeted approaches to thrombus inhibition - An end to the shotgun approach
21. Norephinephrine human platelet activation in vivo is only partially counteracted by aspirin
22. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or usually large vWF multimers, requires adenosine diphosphate and is resistant to aspirin
23. Aspirin and allergic diseases: A review
24. Unfractionated heparin in acute coronary syndromes: Has its time come and gone?
25. Optimal therapeutic level of heparin therapy in patients with venous thromboembolism
26. The weight-based heparin dosing nomogram compared with a "standard care" nomogram
27. Appropriate use of heparin
28. A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease
29. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) IIb trial
30. College of American Pathologist Conference XXXI on laboratory monitoring of anticoagulant therapy. Laboratory monitoring of unfractionated heparin therapy
31. The antiplatelet effects of ticlopidine and clopidogrel
32. Combined ADP and thromboxane A2 antagonism prevents cyclic flow variations in stenosed and endothelium injured arteries in nonhuman primates
33. Ticlopidine: An updated review of its pharmacology and therapeutic use in platelet-dependent disorders
34. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients
35. Thrombotic thrombocytopenic purpura associated with clopidogrel
36. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. Evaluation of platelet IIb-IIIa inhibitor for stenting
37. Antiplatelet drugs: A comparative review
38. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study
39. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
40. A clinical trial comparing 3 antithrombotic drug regimens after coronary artery stenting
41. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients
42. Clopidogrel, a novel antiplatelet and antithrombotic agent
43. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
44. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin after coronary artery stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS)
45. Rapid onset of inhibition of ADP induced platelet aggregation by a loading dose of clopidogrel
46. Analysis of GP IIb-IIIa receptor number by quantification of 7E3 binding to human platelets
47. Blockade of platelet GP IIb-IIIa receptors as an antithrombotic strategy
48. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric & E3 antibody: Potential implications for the effect of c7E3 fab treatment on acute thrombosis and clinical restenosis
49. Use of a monoclonal antibody directed against the platelet glycoprotein IIb-IIIa receptor in high-risk coronary angtioplasty
50. Effects of platelet glycoprotein IIb-IIIa blockage by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction
51. 3 blockade with percutaneous coronary intervention. Evaluation of platelet IIb-IIIa inhibition for prevention of ischemic complication
52. Platelet glycoprotein IIb-IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
53. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb-IIIa blockade with abciximab: One-year outcome in the EPILOG trial
54. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
55. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb-IIIa blockade. Evaluation of platelet IIb-IIIa inhibitor for stenting
56. Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: Results of the EPISTENT trial
57. Abxicimab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial
58. Effects of platelet glycoprotein IIb-IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized efficacy study of tirofiban for outcomes and restenosis
59. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet receptor inhibition in ischemic syndrome management
60. Inhibition of the platelet glycoprotein IIa/IIIb receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable angina signs and symptoms
61. New platelet glycoprotein IIb/IIa inhibitor trials in percutaneous coronary intervention
62. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes
63. Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: A review of the IMPACT II trial. Integrelin to minimize platelet aggregation and coronary thrombosis
64. Effect of Ca+ on GP IIb-IIIa interactions with integrelin
65. Design and methodology of the PURSUIT trial: Evaluating eptifibatide for acute ischemic coronary syndromes. Platelet glycoprotein IIb-IIIa in unstable angina: Receptor suppression using integrilin therapy
66. Enhanced suppression of platelet receptor glycoprotein IIb/IIIa using integrilin therapy. ESPRIT trial
67. Low-molecular-weight heparins
68. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
69. Low-molecular-weight heparin during instability in coronary artery disease
70. Long-term lower-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomized multicentre study
71. Fragmin in unstable angina pectoris or in non-Q wave acute myocardial infarction (the FRIC study)
72. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: Results from the ESSENCE randomized trial
73. Antithrombin agents: The new class of anticoagulant and antithrombotic drugs
74. Direct thrombin inhibitors for the treatment of arterial thrombosis: Potential differences between bivalirudin and hirudin
75. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty
76. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
77. A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina
78. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO)
79. Direct thrombin inhibition and thrombolytic therapy: Rationale for the hirulog and early reperfusion/occlusion (HERO-2) trial
80. Comparison of the effects of two doses of recombinant hirudin with heparin in patients with acute myocardial infarction without ST segment elevation
81. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina and revascularisation procedures in patients with acute myocardial ischemia without ST segment elevation: A randomised trial
82. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: Myocardial infarction with novastan and TPA (MINT) study